marketcaparena
Search

    AXSM

    Axsome Therapeutics, Inc.

    Company overview

    Market capitalization
    $10.16B
    Employees
    1,220
    Latest publication
    2026-09-29
    About Axsome Therapeutics, Inc.

    Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ3 20212021-09-30 · USDQ2 20212021-06-30 · USDQ1 20212021-03-31 · USDQ4 20202020-12-31 · USDQ3 20202020-09-30 · USDQ2 20202020-06-30 · USDQ1 20202020-03-31 · USD
    Total Revenue218,375,000USD0USD0USD0USD0USD0USD0USD0USD
    Cost Of Revenue13,564,000USD299,742USD277,422USD8,326USD————
    Gross Profit204,811,000USD-299,742USD-277,422USD-8,326USD————
    Research Development46,227,000USD13,180,258USD14,503,326USD16,595,689USD17,384,729USD14,795,493USD10,542,957USD27,521,400USD
    Selling General Administrative208,137,000USD20,226,884USD16,344,361USD10,961,449USD10,359,507USD6,331,308USD7,235,877USD4,970,057USD
    Selling And Marketing Expenses164,113,000USD——286,923USD————
    General And Administrative Expenses24,615,000USD———————
    Total Operating Expenses254,457,000USD33,407,142USD30,847,687USD27,844,061USD27,744,236USD21,126,801USD17,778,834USD32,491,457USD
    Operating Income-49,646,000USD-33,407,142USD-30,847,687USD-27,844,061USD-27,744,236USD-21,126,801USD-17,778,834USD-32,491,457USD
    Total Other Income Expense Net-1,540,000USD-1,475,535USD-1,436,522USD-1,415,909USD-1,420,411USD-1,798,014USD-548,158USD7,311USD
    Interest Income1,660,000USD——————7,311USD
    Interest Expense-3,200,000USD1,475,535USD1,436,522USD1,415,909USD1,473,989USD551,002USD548,158USD7,311USD
    Income Before Tax-51,186,000USD-34,882,677USD-32,284,209USD-29,259,970USD-29,164,647USD-22,924,815USD-18,326,992USD-32,484,146USD
    Income Tax Expense128,000USD——262,764USD-7,658USD545,480USD—-5,436USD
    Net Income-51,314,000USD-34,882,677USD-32,284,209USD-29,259,970USD-29,164,647USD-22,924,815USD-18,326,992USD-32,484,146USD
    Net Interest Income—-1,475,535USD-1,436,522USD-1,415,909USD-1,473,989USD-551,002USD-548,158USD7,311USD
    Net Income From Continuing Ops—-34,882,677USD-32,284,209USD-29,259,970USD-29,218,225USD-22,924,815USD-18,326,992USD-32,484,146USD
    Ebit—-33,407,142USD-30,847,687USD-27,844,061USD-27,690,658USD-22,373,813USD-17,778,834USD-32,491,457USD
    Ebitda—-33,107,400USD-30,570,265USD-27,572,971USD-27,629,422USD-22,368,291USD-17,773,310USD-32,486,021USD
    Depreciation And Amortization—299,742USD277,422USD271,090USD61,236USD5,522USD5,524USD5,436USD
    Reconciled Depreciation—299,742USD277,422USD271,090USD61,236USD5,522USD5,524USD5,436USD
    Non Operating Income Net Other—-1,475,535USD-1,436,522USD-1,415,909USD-1,473,989USD—-548,158USD7,311USD
    Net Income Applicable To Common Shares—-34,882,677USD-32,284,209USD-29,259,970USD-29,164,647USD-22,924,815USD-18,326,992USD-32,484,146USD
    Source0001193125-26-342360DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20212021-12-31 · USDFY 20162016-12-31 · USDFY 20152015-12-31 · USD
    Total Revenue8,819,786USD0USD0USD
    Cost Of Revenue1,155,663USD20,484USD3,542USD
    Gross Profit-1,155,663USD-20,484USD-3,542USD
    Research Development58,060,725USD21,199,860USD6,776,987USD
    Selling General Administrative66,646,205USD6,343,648USD2,419,289USD
    Selling And Marketing Expenses205USD——
    Total Operating Expenses124,706,930USD27,543,508USD9,196,276USD
    Operating Income-124,706,930USD-27,543,508USD-9,196,276USD
    Interest Expense5,696,062USD132,424USD914,952USD
    Net Interest Income-5,696,062USD-132,424USD—
    Income Before Tax-130,402,992USD-27,201,653USD-10,559,579USD
    Income Tax Expense4,540,399USD586,219USD1,359,761USD
    Tax Provision0USD——
    Net Income-134,943,391USD-27,201,653USD-12,210,579USD
    Net Income From Continuing Ops-130,402,992USD-27,201,653USD-12,210,579USD
    Ebit-124,706,930USD-27,543,508USD-9,196,276USD
    Ebitda-123,551,267USD-27,523,024USD-9,192,734USD
    Depreciation And Amortization1,155,663USD20,484USD3,542USD
    Reconciled Depreciation1,155,663USD——
    Total Other Income Expense Net-5,696,062USD341,855USD-1,363,303USD
    Non Operating Income Net Other-5,696,062USD-132,424USD—
    Net Income Applicable To Common Shares-130,402,992USD-27,201,653USD-12,210,580USD
    Interest Income—132,420USD569,790USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets761,447,000USD713,607,000USD689,805,000USD669,250,000USD639,785,000USD596,671,000USD568,498,000USD561,458,000USD
    Cash And Equivalents319,850,000USD———————
    Total Current Assets656,569,000USD611,206,000USD588,986,000USD565,342,000USD536,620,000USD494,634,000USD485,064,000USD479,113,000USD
    Other Current Assets21,377,000USD23,523,000USD13,651,000USD19,789,000USD16,338,000USD16,007,000USD11,978,000USD13,411,000USD
    Total Liabilities678,143,000USD———————
    Total Current Liabilities460,446,000USD439,211,000USD378,836,000USD360,290,000USD342,099,000USD243,914,000USD230,104,000USD196,187,000USD
    Total Stockholder Equity83,304,000USD54,587,000USD88,295,000USD73,727,000USD73,075,000USD53,205,000USD57,015,000USD92,898,000USD
    Total Equity Including Noncontrolling Interest83,304,000USD———————
    Short Long Term Debt70,000,000USD70,000,000USD70,000,000USD70,000,000USD70,000,000USD———
    Long Term Debt117,958,000USD117,850,000USD117,746,000USD117,642,000USD117,540,000USD181,377,000USD180,710,000USD180,002,000USD
    Net Receivables277,459,000USD251,062,000USD224,464,000USD196,507,000USD198,825,000USD161,398,000USD142,001,000USD124,096,000USD
    Inventory37,883,000USD31,515,000USD27,938,000USD23,774,000USD18,441,000USD16,319,000USD15,732,000USD14,265,000USD
    Property Plant Equipment Net20,031,000USD20,014,000USD20,858,000USD26,654,000USD23,139,000USD24,067,000USD5,967,000USD5,730,000USD
    Goodwill12,042,000USD———————
    Intangible Assets37,358,000USD38,947,000USD40,519,000USD42,126,000USD43,733,000USD45,322,000USD46,894,000USD48,501,000USD
    Accounts Payable78,969,000USD106,702,000USD65,537,000USD54,227,000USD91,628,000USD85,659,000USD71,997,000USD64,253,000USD
    Short Term Debt646,000USD73,821,000USD72,979,000USD73,233,000USD72,351,000USD2,270,000USD3,256,000USD2,907,000USD
    Common Stock5,000USD5,000USD5,000USD5,000USD5,000USD5,000USD5,000USD5,000USD
    Retained Earnings-1,421,817,000USD-1,370,503,000USD-1,305,961,000USD-1,277,402,000USD-1,230,173,000USD-1,182,200,000USD-1,122,787,000USD-1,047,875,000USD
    Total Liab—659,020,000USD601,510,000USD595,523,000USD566,710,000USD543,466,000USD511,483,000USD468,560,000USD
    Other Current Liab—258,688,000USD240,320,000USD232,830,000USD178,120,000USD155,025,000USD153,891,000USD128,534,000USD
    Capital Stock—5,000USD5,000USD5,000USD5,000USD5,000USD5,000USD5,000USD
    Good Will—12,042,000USD12,042,000USD12,042,000USD12,042,000USD12,042,000USD12,042,000USD12,042,000USD
    Cash—305,106,000USD322,933,000USD325,272,000USD303,016,000USD300,910,000USD315,353,000USD327,341,000USD
    Cash And Short Term Investments—305,106,000USD322,933,000USD325,272,000USD303,016,000USD300,910,000USD315,353,000USD327,341,000USD
    Net Debt—-85,206,000USD-81,638,000USD-106,676,000USD-85,709,000USD-89,678,000USD-122,398,000USD-135,041,000USD
    Short Long Term Debt Total—219,900,000USD241,295,000USD218,596,000USD217,307,000USD211,232,000USD192,955,000USD192,300,000USD
    Property Plant Equipment Gross—20,581,000USD21,420,000USD22,259,000USD23,139,000USD24,067,000USD5,967,000USD6,413,000USD
    Common Stock Shares Outstanding—51,198,349shares50,631,337shares50,021,851shares49,442,000shares48,871,163shares48,541,905shares48,140,519shares
    Non Current Assets Total—102,401,000USD100,819,000USD103,908,000USD103,165,000USD102,037,000USD83,434,000USD82,345,000USD
    Non Current Liabilities Total—219,809,000USD222,674,000USD235,233,000USD224,611,000USD299,552,000USD281,379,000USD272,373,000USD
    Non Current Liabilities Other—73,730,000USD77,540,000USD89,870,000USD79,655,000USD90,590,000USD91,680,000USD82,980,000USD
    Non Currrent Assets Other—31,398,000USD27,400,000USD23,086,000USD24,251,000USD20,606,000USD18,531,000USD16,072,000USD
    Net Working Capital—171,995,000USD210,150,000USD205,052,000USD194,521,000USD250,720,000USD254,960,000USD282,926,000USD
    Unclassified Current Liabilities—-70,000,000USD-70,000,000USD-70,000,000USD-70,000,000USD———
    Unclassified Non Current Liabilities—28,229,000USD27,388,000USD27,721,000USD27,416,000USD27,585,000USD8,989,000USD9,391,000USD
    Unclassified Equity—1,425,080,000USD1,394,246,000USD1,351,119,000USD1,303,238,000USD1,235,395,000USD1,179,792,000USD1,140,763,000USD
    Source0001193125-26-342360DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets689,805,000USD568,498,000USD588,236,000USD331,476,000USD87,785,058USD186,134,323USD220,549,760USD15,379,279USD
    Intangible Assets40,519,000USD46,894,000USD53,286,000USD59,661,000USD————
    Other Current Assets13,651,000USD11,978,000USD8,115,000USD2,781,000USD45,286USD148,373USD413,095USD1,246,360USD
    Total Liab601,510,000USD511,483,000USD397,259,000USD221,920,000USD72,154,706USD72,341,414USD41,827,371USD14,441,358USD
    Total Stockholder Equity88,295,000USD57,015,000USD190,977,000USD109,556,000USD15,630,352USD113,792,909USD178,722,389USD937,921USD
    Other Current Liab240,320,000USD153,891,000USD96,908,000USD57,531,000USD9,295,180USD8,713,249USD683,178USD3,843,299USD
    Common Stock5,000USD5,000USD5,000USD4,000USD3,782USD3,737USD3,693USD3,009USD
    Capital Stock5,000USD5,000USD5,000USD4,350USD3,782USD3,737USD3,693USD3,009USD
    Retained Earnings-1,305,961,000USD-1,122,787,000USD-835,571,000USD-596,333,000USD-409,199,085USD-278,796,093USD-175,895,493USD-107,550,307USD
    Good Will12,042,000USD12,042,000USD12,042,000USD10,310,000USD0USD———
    Cash322,933,000USD315,353,000USD386,193,000USD200,842,000USD86,472,854USD183,876,453USD219,966,167USD13,968,742USD
    Cash And Short Term Investments322,933,000USD315,353,000USD386,193,000USD200,842,000USD86,472,854USD183,876,453USD219,966,167USD13,968,742USD
    Total Current Assets588,986,000USD485,064,000USD504,263,000USD245,642,000USD86,518,140USD184,024,826USD220,379,262USD15,215,102USD
    Total Current Liabilities378,836,000USD230,104,000USD138,854,000USD96,561,000USD23,065,184USD23,437,858USD24,494,745USD10,821,938USD
    Net Debt-81,638,000USD-122,398,000USD-199,821,000USD-106,158,000USD-36,762,657USD-133,752,310USD-200,031,249USD-7,057,928USD
    Short Term Debt72,979,000USD3,256,000USD1,267,000USD425,000USD620,675USD1,220,587USD2,602,292USD3,291,394USD
    Short Long Term Debt70,000,000USD—————2,602,292USD3,291,394USD
    Short Long Term Debt Total241,295,000USD192,955,000USD186,372,000USD94,684,000USD49,710,197USD50,124,143USD19,934,922USD6,910,814USD
    Long Term Debt117,746,000USD180,710,000USD178,070,000USD94,258,888USD49,089,522USD48,321,848USD17,332,626USD3,619,420USD
    Net Receivables224,464,000USD142,001,000USD94,820,000USD37,699,000USD0USD———
    Inventory27,938,000USD15,732,000USD15,135,000USD4,320,000USD0USD———
    Accounts Payable65,537,000USD71,997,000USD40,679,000USD38,605,000USD13,149,329USD13,504,022USD10,943,325USD3,687,245USD
    Property Plant Equipment Net20,858,000USD5,967,000USD7,618,000USD1,142,000USD944,008USD1,792,122USD30,623USD51,832USD
    Property Plant Equipment Gross21,420,000USD5,967,000USD7,618,000USD1,142,813USD944,008USD1,792,122USD30,623USD51,832USD
    Common Stock Shares Outstanding49,747,178shares47,914,000shares45,425,212shares40,655,941shares37,618,599shares37,206,928shares34,020,257shares26,883,656shares
    Non Current Assets Total100,819,000USD83,434,000USD83,973,000USD85,834,000USD1,266,918USD2,109,497USD170,498USD164,177USD
    Non Current Liabilities Total222,674,000USD281,379,000USD258,405,000USD125,359,000USD49,089,522USD48,903,556USD17,332,626USD3,619,420USD
    Non Current Liabilities Other77,540,000USD91,680,000USD73,300,000USD31,100,000USD—581,708USD——
    Non Currrent Assets Other27,400,000USD18,531,000USD11,027,000USD14,721,000USD322,910USD317,375USD139,875USD112,345USD
    Net Working Capital210,150,000USD254,960,000USD365,409,000USD149,080,611USD63,452,956USD160,586,968USD195,884,517USD4,393,164USD
    Unclassified Current Liabilities-70,000,000USD—————-2,602,292USD-6,609,080USD
    Unclassified Non Current Liabilities27,388,000USD8,989,000USD7,035,000USD-31,099,888USD————
    Unclassified Equity1,394,246,000USD1,179,792,000USD1,026,538,000USD705,880,650USD424,821,873USD392,581,528USD354,610,496USD108,482,210USD
    Accumulated Other Comprehensive Income——0USD—0USD—0USD—
    Other Liab———31,100,000USD————
    Other Assets———14,721,101USD-426,141,641USD2,109,497USD139,875USD112,345USD
    Net Tangible Assets———39,585,637USD15,630,352USD113,792,909USD178,722,389USD937,921USD
    Unclassified Non Current Assets———-14,721,101USD—-2,109,497USD——
    Current Deferred Revenue——————10,265,950USD3,317,686USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation3,420,000USD
    Stock Based Compensation50,586,000USD
    Other Non Cash Items0USD
    Change To Account Receivables-52,995,000USD
    Change To Inventory-9,000,000USD
    Change To Liabilities13,432,000USD
    Change In Working Capital-48,563,000USD
    Operating Cash Flow-53,652,000USD
    Capital Expenditures-571,000USD
    Investing Cash Flow-571,000USD
    Net Debt Issuance-141,882,000USD
    Net Common Stock Issuance-12,135,000USD
    Unclassified Financing Cash Flow205,157,000USD
    Financing Cash Flow51,140,000USD
    Change In Cash-3,083,000USD
    End Cash Flow319,850,000USD
    Source0001193125-26-342360DeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-64,542,000USD-28,559,000USD-47,229,000USD-47,973,000USD-59,413,000USD-74,912,000USD-64,602,000USD-79,345,000USD
    Depreciation2,367,000USD2,274,000USD2,411,000USD1,709,000USD1,721,000USD2,073,000USD2,061,000USD1,993,000USD
    Stock Based Compensation23,438,000USD22,730,000USD23,103,000USD24,611,000USD23,308,000USD21,986,000USD21,660,000USD21,382,000USD
    Other Non Cash Items985,000USD-8,272,000USD13,978,000USD3,561,000USD1,158,000USD11,852,000USD38,324,000USD2,979,000USD
    Change To Account Receivables-26,598,000USD-27,957,000USD2,318,000USD-37,428,000USD-19,396,000USD-17,905,000USD-3,754,000USD-18,907,000USD
    Change To Inventory-4,872,000USD-3,491,000USD-4,994,000USD-1,777,000USD-249,000USD-4,143,000USD1,288,000USD690,000USD
    Change In Working Capital17,052,000USD-6,826,000USD8,783,000USD-14,331,000USD-10,149,000USD12,799,000USD-16,074,000USD22,881,000USD
    Total Cash From Operating Activities-20,700,000USD-18,653,000USD1,046,000USD-32,423,000USD-43,375,000USD-26,202,000USD-18,631,000USD-30,110,000USD
    Capital Expenditures-121,000USD-71,000USD-58,000USD-13,000USD-338,000USD-30,000USD-150,000USD-52,000USD
    Free Cash Flow-20,821,000USD-18,724,000USD988,000USD-32,436,000USD-43,713,000USD-26,232,000USD-18,481,000USD-30,162,000USD
    Total Cashflows From Investing Activities-121,000USD-71,000USD-58,000USD-13,000USD-338,000USD-30,000USD-90,000USD-52,000USD
    Net Borrowings-672,000USD-541,000USD-664,000USD-2,506,000USD-401,000USD-330,000USD-311,000USD—
    Total Cash From Financing Activities2,994,000USD16,385,000USD21,268,000USD34,542,000USD29,270,000USD14,244,000USD30,405,000USD14,378,000USD
    Issuance Of Capital Stock6,343,000USD5,675,000USD9,946,000USD32,633,000USD19,650,000USD16,419,000USD13,101,000USD11,264,000USD
    Change In Cash-17,827,000USD-2,339,000USD22,256,000USD2,106,000USD-14,443,000USD-11,988,000USD11,684,000USD-15,784,000USD
    Begin Period Cash Flow322,933,000USD325,272,000USD303,016,000USD300,910,000USD315,353,000USD327,341,000USD315,657,000USD331,441,000USD
    End Period Cash Flow305,106,000USD322,933,000USD325,272,000USD303,016,000USD300,910,000USD315,353,000USD327,341,000USD315,657,000USD
    Other Cashflows From Investing Activities-121,000USD280,000USD-409,000USD-13,000USD-338,000USD—-240,000USD—
    Other Cashflows From Financing Activities-12,563,000USD-3,989,000USD-3,348,999USD-3,091,000USD10,021,000USD-1,845,000USD17,615,000USD-3,216,000USD
    Unclassified Financing Cash Flow9,886,000USD15,240,000USD15,334,999USD7,506,000USD——10,155,000USD18,922,000USD
    Investments——-58,000USD-13,000USD-338,000USD-30,000USD-90,000USD-52,000USD
    Sale Purchase Of Stock——————2,946,000USD-1,328,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USD
    Net Income-183,174,000USD-287,216,000USD-239,238,000USD-187,134,000USD-102,900,600USD-68,345,186USD-30,965,464USD-28,943,392USD
    Depreciation9,064,000USD7,958,000USD6,834,000USD4,402,000USD77,718USD37,330USD48,935USD42,557USD
    Stock Based Compensation93,752,000USD85,218,000USD62,620,000USD37,726,000USD14,756,206USD6,115,160USD1,754,974USD2,072,210USD
    Other Non Cash Items9,476,000USD31,730,000USD53,096,000USD4,825,000USD7,951,054USD649,993USD375,635USD470,521USD
    Change To Account Receivables-82,463,000USD-47,181,000USD-57,121,000USD-37,699,000USD177,500USD-37,698,868USD—0USD
    Change To Inventory-15,670,000USD-2,439,000USD-8,156,000USD-5,275,000USD-177,500USD-1,330,916USD—0USD
    Change In Working Capital-22,523,000USD33,900,000USD-28,392,000USD23,670,000USD412,041USD15,167,644USD1,523,219USD-759,548USD
    Total Cash From Operating Activities-93,405,000USD-128,410,000USD-145,080,000USD-116,511,000USD-78,456,569USD-46,375,059USD-30,053,701USD-26,471,652USD
    Capital Expenditures-480,000USD-270,000USD-582,000USD-702,000USD-45,891USD-16,121USD-32,696USD-9,898USD
    Free Cash Flow-93,885,000USD-128,680,000USD-145,662,000USD-117,213,000USD-78,502,460USD-46,391,180USD-30,086,397USD-26,481,550USD
    Total Cashflows From Investing Activities-480,000USD-270,000USD-582,000USD-53,702,000USD-45,891USD-16,121USD-32,696USD-9,898USD
    Net Borrowings-4,112,000USD-990,000USD85,000,000USD45,000,000USD27,237,391USD12,761,111USD-3,359,330USD-277,778USD
    Total Cash From Financing Activities101,465,000USD57,840,000USD331,013,000USD284,582,000USD42,412,746USD252,388,605USD10,034,016USD23,884,176USD
    Issuance Of Capital Stock67,904,000USD40,784,000USD258,750,000USD236,788,056USD14,125,506USD238,233,817USD12,881,321USD—
    Change In Cash7,580,000USD-70,840,000USD185,351,000USD114,369,000USD-36,089,714USD205,997,425USD-20,052,381USD-2,597,374USD
    Begin Period Cash Flow315,353,000USD386,193,000USD200,842,000USD86,473,000USD219,966,167USD13,968,742USD34,021,123USD36,618,497USD
    End Period Cash Flow322,933,000USD315,353,000USD386,193,000USD200,842,000USD183,876,453USD219,966,167USD13,968,742USD34,021,123USD
    Other Cashflows From Investing Activities-480,000USD-270,000USD—-53,702,109,000,000USD-45,891,000,000USD-16,121,000,000USD-32,696,000,000USD-9,898,000,000USD
    Other Cashflows From Financing Activities-17,050,000USD18,046,000USD-12,737,000USD-4,181,000USD-52,760USD1,393,677USD486,028USD484,613USD
    Unclassified Financing Cash Flow54,723,000USD—260,585,000USD288,275,800USD————
    Investments—-270,000USD-582,000USD-53,702,109USD-45,891USD-16,121USD-32,696USD-9,898USD
    Sale Purchase Of Stock——-1,835,000USD-531,831USD15,175,355USD239,627,494USD13,393,346USD24,161,950USD
    Change To Liabilities———25,455,983USD324,819USD14,361,909USD1,415,554USD-645,717USD
    Dividends Paid———-43,980,969USD———0USD
    Unclassified Investing Cash Flow———53,702,109,702,109USD45,891,045,891USD16,121,016,121USD32,696,032,696USD9,898,009,898USD
    Cash And Cash Equivalents Changes————-36,089,714USD205,997,425USD-20,052,381USD-2,597,374USD
    Unclassified Operating Cash Flow————1,247,012USD—-2,791,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    Commercial Products

    Period endPeriodValueUnitSource
    No published observations yet.

    FDA-Approved Treatments

    Period endPeriodValueUnitSource
    No published observations yet.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductMilestone Revenue546,000USD0001193125-26-342360
    Q2 2026Quarterly · 2026-06-30ProductProduct216,355,000USD0001193125-26-342360
    Q2 2026Quarterly · 2026-06-30ProductRoyalty1,474,000USD0001193125-26-342360
    Q2 2026Quarterly · 2026-06-30ProductRoyalty And Milestone Revenue2,020,000USD0001193125-26-342360
    FY 2025Yearly · 2025-12-31ProductLicense0USD0001193125-26-064267
    FY 2025Yearly · 2025-12-31ProductProduct633,796,000USD0001193125-26-064267
    FY 2025Yearly · 2025-12-31ProductRoyalty And Milestone Revenue4,700,000USD0001193125-26-064267
    Q3 2025Quarterly · 2025-09-30ProductProduct169,784,000USD0001193125-25-262664
    Q3 2025Quarterly · 2025-09-30ProductRoyalty1,208,000USD0001193125-25-262664
    Q2 2025Quarterly · 2025-06-30ProductProduct148,959,000USD0000950170-25-102148
    Q2 2025Quarterly · 2025-06-30ProductRoyalty1,083,000USD0000950170-25-102148
    Q1 2025Quarterly · 2025-03-31ProductProduct120,358,000USD0001193125-26-204274
    Q1 2025Quarterly · 2025-03-31ProductRoyalty1,105,000USD0001193125-26-204274
    Q1 2025Quarterly · 2025-03-31ProductRoyalty And Milestone Revenue1,105,000USD0001193125-26-204274
    FY 2024Yearly · 2024-12-31ProductLicense0USD0001193125-26-064267
    FY 2024Yearly · 2024-12-31ProductProduct381,677,000USD0001193125-26-064267
    FY 2024Yearly · 2024-12-31ProductRoyalty And Milestone Revenue4,016,000USD0001193125-26-064267
    Q3 2024Quarterly · 2024-09-30ProductProduct103,736,000USD0001193125-25-262664
    Q3 2024Quarterly · 2024-09-30ProductRoyalty1,026,000USD0001193125-25-262664
    Q2 2024Quarterly · 2024-06-30ProductProduct86,520,000USD0000950170-25-102148
    Q2 2024Quarterly · 2024-06-30ProductRoyalty646,000USD0000950170-25-102148
    Q1 2024Quarterly · 2024-03-31ProductProduct74,096,000USD0000950170-25-063634
    Q1 2024Quarterly · 2024-03-31ProductRoyalty903,000USD0000950170-25-063634
    FY 2023Yearly · 2023-12-31ProductLicense65,735,000USD0001193125-26-064267
    FY 2023Yearly · 2023-12-31ProductProduct202,460,000USD0001193125-26-064267
    FY 2023Yearly · 2023-12-31ProductRoyalty And Milestone Revenue2,405,000USD0001193125-26-064267
    Q3 2023Quarterly · 2023-09-30ProductProduct57,127,000USD0000950170-24-124758
    Q3 2023Quarterly · 2023-09-30ProductRoyalty667,000USD0000950170-24-124758
    FY 2022Yearly · 2022-12-31ProductLicense0USD0000950170-25-022457
    FY 2022Yearly · 2022-12-31ProductProduct50,037,000USD0000950170-25-022457
    FY 2022Yearly · 2022-12-31ProductRoyalty And Milestone Revenue0USD0000950170-25-022457

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.